



Prana AGM Investor Conference Call

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – November 12th 2018: Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) invites investors unable to attend the Company's Annual General Meeting to participate via teleconference.

The AGM is scheduled for 9.30am (Australian Eastern Daylight Time) on Friday 16th November at the RACV City Club, Level 2, 501 Bourke Street, Melbourne. Registration is from 9.15am.

To pre-register for the conference call, with a calendar invite sent directly to you, [click here](#).

Conference ID: 467761

Dial in details

Australian Toll Free	1800 558 698
Australian alternative	1800 809 971
Hong Kong	800 966 806
New Zealand	0800 453 055
Singapore	800 101 2785
United Kingdom	0800 051 8245
United States	855 881 1339

Other locations are available on request.

The AGM presentation will be available at www.asx.com.au 30 minutes prior to the start time. If you would like to submit a question, please email bwalsh@we-buchan.com by 5pm AEDT on Thursday 16th November.

END

Contacts:

Investor Relations

Rebecca Wilson

E: rwilson@we-buchan.com.au

Tp: +61 3 9866 4722

Media

Ben Walsh

E: bwalsh@we-buchan.com

Tp: +61 2 9237 2801

About Prana Biotechnology:

Prana's lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of α -synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various forms of atypical parkinsonism such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).

For further information please visit the Company's web site at www.pranabio.com.



Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factors including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.